TACSTD2 and neoplasm: Considering TROP2 expression in more than 10% of tumor cells is positive, moderate-to-strong intensity of TROP2 expression occurred in 662 cases (82.0%) in Cohort 1, 59 cases (89.4%) in Cohort 2, and 23 cases (88.5%) in Cohort 3 (Table 1a).